(MENAFN- GlobeNewsWire - Nasdaq) As Per SNS Insider, The Growth Hormone Deficiency market is poised for substantial growth, driven by advancements in diagnostic technologies, increasing awareness, and innovations in hormone delivery systems that enhance patient adherence and treatment outcomes.Pune, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Growth Hormone Deficiency Market Size & Share Analysis:
“According to SNS Insider, The Growth hormone deficiency Market was valued at USD 5.4 billion in 2023 and is projected to reach USD 8.5 billion by 2032 and grow at a CAGR of 5.0% over the forecast period 2024-2032.”
Market Overview
The global growth hormone deficiency (GHD) market is witnessing significant expansion due to the rising prevalence of growth hormone disorders among pediatric and adult populations. Key growth drivers include advancements in diagnostic tools and therapies such as prefilled pen systems and precision medicine, which have substantially improved treatment options. Increased investment in pharmaceutical research and development (R&D) is leading to the creation of innovative therapies.
Additionally, the rise of online pharmacies and specialty clinics is improving patient access to growth hormone treatments, particularly in emerging markets. The growing patient base and emphasis on early diagnosis and treatment are fueling global demand for growth hormone therapies.
Get a Sample Report of Growth Hormone Deficiency Market@
Key Growth Hormone Deficiency Companies:
F. Hoffmann-La Roche Ltd. Mylan N.V. Teva Pharmaceutical Industries Ltd. Sanofi Pfizer Inc. GSK plc Novartis AG Zydus Group AstraZeneca Bayer AG Sun Pharmaceutical Industries Ltd. Merck & Co. Inc. Bristol-Myers Squibb Company Eli Lilly and Company Cipla Inc. Ipsen Pharma Novo Nordisk A/S Abbott Abbvie Inc
Growth Hormone Deficiency Market Report Scope:
| Report Attributes | Details |
| Market Size in 2023 | US$ 5.4 Billion |
| Market Size by 2032 | US$ 8.5 Billion |
| CAGR | CAGR of 5.0% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
Key Segments Covered:
By Brand
Norditropin Genotropin Humatrope Saizen Omnitrope Others
By Application
Growth Hormone Deficiency Turner Syndrome Idiopathic Short Stature Prader–Willi Syndrome Small for Gestational Age Others
By End-User
Hospital Pharmacy Retail Pharmacy Online Pharmacy & Specialty Pharmacy
Segment Analysis
By Brand
In 2023, Norditropin, manufactured by Novo Nordisk, led the growth hormone deficiency market with revenue of USD 1.6 billion, maintaining a significant market share. Norditropin is anticipated to continue its leadership, growing at a CAGR of 4.9% from 2024 to 2032. This dominance is attributed to Novo Nordisk's strong brand reputation, extensive clinical backing, and user-friendly preloaded pen system. Conversely, Genotropin, with the second-largest market share, generated USD 1.4 billion in 2023 and is projected to reach USD 2.1 billion by 2032. Genotropin supports growth and immune function but has limitations in specific patient populations.
By Application
In the growth hormone deficiency market, the Idiopathic Short Stature (ISS) segment was the dominant player in 2023, holding a 45% market share and generating USD 2.5 billion in revenue. This segment is expected to grow to USD 3.7 billion by 2032, with a CAGR of 4.8%, driven by increased awareness and the prevalence of ISS among children. The Pediatric Growth Hormone Deficiency segment is the fastest-growing, capturing a 30% market share with USD 1.5 billion in revenue. It is projected to grow at a CAGR of 5.3%, fueled by advancements in early diagnosis and treatment.
By End-user
Hospital pharmacies led the growth hormone deficiency market in 2023, commanding a 48% share and generating USD 2.7 billion in revenue. This segment is crucial for managing prescription growth hormone medications and ensuring compliance, with a projected growth rate of 4.8% CAGR from 2024 to 2032. The Specialty Pharmacies segment holds the second-largest share at 35%, with USD 1.8 billion in revenue. It is expected to grow at a faster rate of 5.3% CAGR, driven by its specialized services and tailored care for complex GHD treatments.
Do you have any specific queries or need any customization research on Growth Hormone Deficiency Market, Enquire Now@
Regional Analysis
Dominating Region: North America
North America held the largest share of the growth hormone deficiency market in 2023, due to high levels of awareness, advanced healthcare infrastructure, and substantial R&D investments. The U.S. healthcare system's capability to diagnose and treat GHD early, coupled with favorable reimbursement policies, has contributed to North America's market leadership.
Fastest-Growing Region: Asia-Pacific
Asia-Pacific is expected to be the fastest-growing region during the forecast period due to the increasing incidence of growth hormone deficiency and rising awareness. The region has experienced significant growth in healthcare expenditure, particularly in China and India, where access to early diagnosis and treatment has improved markedly. The growing presence of online pharmacies and increased investments from global pharmaceutical companies are further accelerating market growth in Asia-Pacific.
Recent Developments
June 2024: Novo Nordisk launched a new version of Norditropin in China, featuring improved user-friendly injection devices. March 2024: Pfizer expanded its global distribution network for Genotropin, focusing on emerging markets. December 2023: Merck launched Saizen growth hormone therapy in India, targeting pediatric patients. October 2023: Sandoz expanded its Omnitrope distribution across the European Union, increasing access through online pharmacies. July 2023: Eli Lilly introduced a new Humatrope prefilled pen system to enhance patient adherence in the U.S. February 2023: Pfizer announced an R&D partnership with a biotech firm to develop a long-acting growth hormone therapy.
Key Takeaways
The growth hormone deficiency market is projected to reach USD 8.51 billion by 2032. Norditropin leads the market, with Genotropin expected to be the fastest-growing segment. Growth hormone deficiency remains the largest indication, supported by early diagnosis and treatment needs. North America dominates the market, while Asia-Pacific is forecasted to grow the fastest. Recent product launches and strategic partnerships are driving innovation and global market expansion.
Buy a Single-User PDF of Growth Hormone Deficiency Market Analysis & Outlook Report 2024-2032@
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
Incidence and Prevalence (2023) Prescription Trends, (2023), by Region Drug Volume: Production and usage volumes of pharmaceuticals. Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
7. Growth Hormone Deficiency Market Segmentation, by Brand
8. Growth Hormone Deficiency Market Segmentation, by Application
9. Growth Hormone Deficiency Market Segmentation, by End-User
10 Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
Access Complete Report Details of Growth Hormone Deficiency Market Outlook 2024-2032@
[For more information or need any customization research mail us at ...]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us:
Akash Anand – Head of Business Development & Strategy
...
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
MENAFN10092024004107003653ID1108657315
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.